Consumption of BCAAs restored cognitive performance by correcting injury-induced alterations in net synaptic efficacy. (A) Consumption of 100 mM each of leucine, isoleucine, and valine (LIV) for 5 days restored hippocampal BCAA levels. (B) Consumption of the LIV treatment significantly increased both alanine and glutamine concentrations (P < 0.05). Both retrograde (C) and an anterograde (D) contextual fear conditioning tests demonstrated significant cognitive impairment (P < 0.05) after LFPI. This was completely reversed by the consumption of the LIV treatment. In contrast, phenylalanine consumption (100 mM; LFPI-Phe) had no effect on cognitive performance (P > 0.05). Bars indicate the average percentage of “fear behaviors” per 5 min. Insets show a representative sample of the percentage of “fear behaviors” on a per-minute basis. In area CA1 (E) and dentate gyrus (F), consumption of the LIV treatment restored net synaptic efficacy (P < 0.05), whereas consumption of phenylalanine (100 mM) had no effect (P > 0.05). Insets depict representative waveforms collected at maximal stimulation. Scale bar, 0.5 mV/10 ms. (A and B) n = 6 samples. (C) Sham, LFPI and LFPI-LIV had n = 12, 11, and 9, respectively. (D) Sham, LFPI. LFPI-LIV, and LFPI-Phe had n = 14, 11, 10, and 10, respectively. (E and F) n = 8 samples. For all panels, data are means ± SEM *Means differ significantly from sham values (P < 0.05). †Means of data collected from LFPI-Phe mice differ significantly from sham values (P < 0.05).